Drug
Dazucorilant
Dazucorilant: highest development phase Phase 2, developed by Corcept Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dazucorilant 300 mg NCT05407324 | Phase 2 | Amyotrophic Lateral Sclerosis |
| Dazucorilant NCT06495944 | Phase 1 | Healthy Adults |
| Dazucorilant NCT06928779 | Phase 1 | Hepatic Impairment |
Latest
No recent events.
Follow Dazucorilant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.